discuss the genetic and acquired disorders of hypophosphatemia and hyperphosphatemia in which FGF23 plays a role. Although Albright could not measure parathyroid hormone, he concluded on the basis of his studies that showed calcemic resistance to parathyroid extract in W.M. that hyperparathyroidism was present. Using a conceptual approach, we suggest that a defect in the skeletal response to parathyroid hormone contributes to hyperparathyroidism in XLH. Finally, at the end of the review, abnormalities in renal phosphate transport that are sometimes found in patients with polyostotic fibrous dysplasia are discussed.
Lessons from Studies of Rare Genetic Disorders
Studies of rare disorders of phosphate metabolism, particularly X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and tumor-induced osteomalacia, have greatly expanded our understanding of phosphate homeostasis (1) (2) (3) (4) . Importantly, these studies have provided insights into the abnormal phosphate regulation seen in common disorders such as chronic kidney disease. The beginning of this journey can be traced to two articles by Albright published in 1937. One was on an unusual case of rickets, and the other was on several cases of polyostotic fibrous dysplasia. Although the two syndromes seemed to be markedly disparate to Albright, at times they shared a common pathophysiologic pathway.
In 1937, Albright et al. (2) reported the first detailed description of vitamin D-resistant rickets (VDRR), later known as XLH. Scriver et al. (4) , while reviewing the classic article by Winters et al. (5) on VDRR, wrote, "The review of the literature begins with reference to the classical report of resistant rickets," a referral to Albright's studies, which contained balance studies performed during a 4-yr period on W.M., a patient with an unusual form of rickets ( Figure 1 ) (2) . In contrast to vitamin D-deficient rickets (VDDR), urinary calcium excretion was high and failed to increase with vitamin D treatment. Urine phosphorus excretion was higher than previously observed in VDDR, and high daily doses of vitamin D (15,000 to 150,000 U), even with phosphate supplementation, did not alter phosphate balance. Nonetheless, a bone biopsy showed the typical histologic changes of VDDR.
An injection of parathyroid extract (PTE) in W.M. failed to produce the expected rise in serum calcium, leading Albright to deduce that parathyroid hormone (PTH) levels were already elevated from a parathyroid adenoma or parathyroid hyperplasia. During a surgical exploration of W.M., a single parathyroid gland that was hyperplastic was removed. After the parathyroidectomy, serum calcium decreased and phosphorus increased but values returned to baseline after 6 wk. Albright postulated that the hypophosphatemia likely resulted from secondary hyperparathyroidism.
In another study, W.M. was given massive doses of vitamin D (1,500,000 U/d). Hypercalcemia developed, calcium crystals formed in the urine, and serum phosphorus increased slightly. Urine phosphorus excretion decreased modestly, and net calcium and phosphorus balance improved. Concomitant with the improvement in biochemical parameters, the rickets partially healed, suggesting to Albright that resistance to vitamin D was incomplete.
Subsequently, Albright performed additional balance studies on W.M. (6) to determine whether the effect of vitamin D on net intestinal phosphate absorption resulted from an increase in absorption or a decrease in re-excretion. Albright concluded that (1) vitamin D primarily regulated calcium homeostasis, (2) the effect of vitamin D on re-excretion of phosphate was negligible, and (3) changes in phosphate metabolism were secondary to changes in serum calcium and PTH. Albright reasoned that the increase in intestinal calcium absorption after administration of high dosages of vitamin D raised serum calcium, which then lowered PTH levels. The decrease in PTH levels produced the increase in urine calcium, the decrease in urine phosphate, and the rise in serum phosphorus.
Further elucidation of the pathophysiology of VDRR evolved slowly after Albright's reports until delineation of critical steps in the vitamin D pathway, development and refinement of assays for PTH and 1,25 dihydroxycholecalciferol [1,25(OH) 2 D], and discovery/development of mouse models of XLH (7-9) accelerated the process. Key discoveries that contributed to further understanding of the pathophysiology in XLH are listed in Table 1 . Several studies established that a circulating factor was the cause of XLH (10 -13). When the genes for the renal phosphate transporters were cloned and found to be present on chromosomes 5, 6, and 9 rather than the X chromosome, it was clear that XLH was not due to a mutation in the renal phosphate transporters (14 -16).
In 1995, the mutated gene that is responsible for XLH, phosphate-regulating gene with homology to endopeptidase on the X chromosome (PHEX), was identified (17). The gene product is an endopeptidase with similarities to other endopeptidases, including neutral endopeptidase, endothelin convertase enzymes ECE1 and ECE2, and Kell antigen (18). PHEX expression was detected in several tissues, but the protein itself was found only in bone and teeth (19). Similarly, Phex was found to be predominantly expressed in the odontoblast, osteocyte, and osteoblast in Hyp mice (18,19); therefore, PHEX/Phex seems to be active primarily in bone. The role of extraosseous PHEX/ Phex to phenotypic expression of XLH is unclear (20 -23). A Figure 1 . An example of the metabolic balance studies that were performed on W.M. at the Massachusetts General Hospital Metabolic Ward. Depicted are changes in urine and fecal calcium and phosphorus, serum calcium and phosphorus, and overall balance of calcium and phosphorus in response to varying dosages of vitamin D, dihydrotachysterol, and PTE. These studies were performed during a 5-yr period. Reprinted from Albright 
Pathogenesis of XLH: Clues from ADHR
A major breakthrough in understanding the pathogenesis of XLH occurred from studies of a rare phosphate-wasting disorder, ADHR. First described by Bianchine et al. in 1971 (24) , ADHR is a rachitic disorder with phenotypic characteristics similar to XLH. The gene that is responsible for ADHR was found to encode a protein, fibroblast growth factor 23 (FGF23) (25). FGF23 was phosphaturic and suppressed renal 1-␣ hydroxylase activity (Figure 2 ) (19,26,27). FGF23 is inactivated by cleavage at a pro-protein convertase consensus site R(176)XXR (179), but in ADHR, the arginine at either position 176 or 179 is mutated. The mutated protein is resistant to cleavage (28 -30), resulting in high levels of active FGF23, phosphate wasting, hypophosphatemia, suppression of calcitriol, and rickets.
As a consequence of the findings in ADHR, FGF23 was 
FGF23 in XLH
Although not all patients with XLH have elevated FGF23 levels (31,33,34), the "normal" levels of FGF23 in some patients with XLH would seem inappropriate for their degree of hypophosphatemia. Furthermore, studies of the Hyp mouse provide compelling evidence for a role of FGF23 (35-37). Initially, it was postulated that FGF23 is a substrate of PHEX and that mutated PHEX is unable to inactivate FGF23; however, more recent evidence suggests that intact FGF23 is not a PHEX substrate (38 -42) , and, therefore, it has been hypothesized that PHEX acts upstream of FGF23 ( Figure 2 ) (42).
XLH is not solely a defect in phosphate transport. Other molecular disorders have been described (Table 2) . It remains unclear whether high levels of FGF23 account for all of these abnormalities. Perhaps the most compelling evidence that FGF23 is critical for the phenotypic expression of XLH comes from studies of mice with inactivating mutations of PHEX. Homozygous FGF23 ablation in these mice produces a phenotypic result that is virtually identical to mice with just FGF23 ablation (35,36). Data from in vitro studies and Hyp and FGF23 knockout models suggest that FGF23 may also be directly involved in bone mineralization (36, 43, 44) , but further studies are needed to determine its precise role.
Other Potential Phosphatonin/Minhibins in XLH
Other phosphatonin/minhibins (factors that inhibit bone mineralization) may also exist in XLH. PHEX has both catalytic and matrix ligand-binding properties and may have more than one substrate (18,45). Mutation of PHEX/Phex could perturb the metabolism of other factors that may contribute to abnormalities in XLH. One possible candidate in XLH is matrix extracellular phosphoglycoprotein (MEPE).
MEPE is found in osteoblasts, odontoblasts, and osteocytes, and its levels are upregulated in Hyp mice (18, 42) . Cleavage of MEPE by cathepsin B releases acidic serine aspartate-rich-MEPE-associated protein (ASARM), which inhibits mineraliza- Figure 2 . The potential interaction between PHEX and FGF23 and the resultant effects on renal phosphate transport and 1,25(OH) 2 D levels. Active FGF23 (FGF23a) produced by the osteocyte normally binds to a receptor that is present on the basolateral membrane (presumably FGFR1) of the DCT, which produces a paracrine factor that inhibits Na-Pi co-transport and 1␣-hydroxylase (CYP27B1) activity in the renal proximal tubule cell (PT). PHEX, produced by osteoblasts, may activate a factor (Fi) to its active form (Fa) upstream from FGF23. Fa in turn inactivates FGF23 (FGF23a to FGF23i). A rise in 1,25(OH) 2 D provides negative feedback by the inhibition of PHEX activity. In XLH, a loss-of-function mutation in PHEX leads to a decrease in Fa, resulting in an increase in FGF23a and the resultant renal phosphate wasting and inappropriately low 1,25(OH) 2 D levels. (55) ; therefore, it is not surprising that standard or even high doses of vitamin D had little effect on serum phosphorus and produced only small changes in urinary phosphate excretion in W.M. With megadoses of vitamin D (1,500,000 U/d), serum calcium rose, whereas serum phosphorus was unchanged (Figure 1 ). The rise in serum calcium may have resulted from a rise in 25(OH)D levels (56), which could have produced a substantial increase in intestinal calcium absorption via direct binding to the vitamin D receptor (VDR). The appearance of calcium crystals in the urine probably reflected an increase in the filtered load of calcium from hypercalcemia that resulted from the enhanced calcium influx and a decreased capacity to deposit calcium in bone. Suppression of PTH by hypercalcemia would have further increased the urine calcium. Stimulation of the VDR by 25(OH)D would also be expected to increase intestinal phosphate absorption, but this effect would be counteracted by the stimulation of FGF23 production by vitamin D.
Other interesting observations that Albright made during his investigation of W.M. included the absence of a calcemic response to PTE, the presence of parathyroid hyperplasia, and the fall in serum calcium and rise in serum phosphorus after removal of a single parathyroid gland. From the last observation, Albright hypothesized that PTH played a central role in the phosphaturia of XLH, but subsequent studies by other investigators have suggested otherwise. PTH levels in XLH were found to be normal when measured with first-generation assays (19,57,58). Furthermore, dose-response studies of Hyp mice performed to determine whether the phosphaturia was due to PTH hypersensitivity actually showed resistance to PTH (59) . Normal parathyroidectomized mice parabiosed to parathyroidectomized Hyp mice developed phosphaturia, indicating a primary role for a circulating factor other than PTH (11,60). Nonetheless, more recently, PTH levels were noted to be elevated in some untreated patients with XLH when intact PTH was measured (61, 62) . Similarly, PTH levels are high in Hyp mice and in some but not all mouse models of FGF23 overexpression (62) (63) (64) (65) . The reason for the variability in PTH levels in XLH is unclear but may depend on the overall balance among factors that regulate PTH levels (Table 3) . Thus, Albright's deduction that PTH levels were elevated in W.M. may have been correct.
The decision to perform a parathyroidectomy on W.M. was prompted by an impaired calcemic response to PTE, similar to that observed in the Hyp mouse (59) . Resistance to the action of PTH in XLH occurs despite the presence of hypophosphatemia. Hypophosphatemia as a result of dietary phosphate restriction shifts the equilibrium operating point to the left of normals (Figure 4) (66) . This leftward shift indicates that hypophosphatemia increases the sensitivity of normal bone to PTH action, and less PTH is needed to maintain a normal serum calcium. By contrast, if the calcemic response to PTH is blunted in XLH, then the PTH-calcium relationship is shifted to the right of normals and indicates that the bone is resistant to PTH action (Figure 4) . Eventually, the persistent need for higher PTH levels to maintain serum calcium could lead to parathyroid hyperplasia (67) . Albright attributed the resistance to PTE to a preexisting elevation in PTH levels, a phenomena now understood to result from homologous receptor desensitization (68) ; however, other factors may have contributed to the resistance, including abnormalities in bone and vitamin D metabolism. PTH resistance has also been observed in patients with VDDR, perhaps from an excess of osteoid and a lack of readily available bone calcium (69, 70) . In XLH, a much larger percentage of the bone surface than normal is covered with broad osteoid seams with few osteoblasts ( Figure 5, A and B) . Also, osteoblast function may be impaired in XLH (59, 71) , which may impede PTH stimulation of osteoclasts and osteocytes and impair calcium exchange from bone. Moreover, bone microradiographs from patients with XLH have shown the presence of defective mineralized bone ( Figure 5 , C and D), which could reduce PTH-induced release of calcium from bone. PTH administration in Hyp mice also has little effect on 1,25(OH) 2 D levels (72, 73) .
Circulating levels of 1,25(OH) 2 D in patients with XLH are low/normal but inappropriate for hypophosphatemia; therefore, the rise in 1,25(OH) 2 D that would normally occur after PTE administration would have been blunted in W.M. and contributed to the impaired calcemic response to PTE (67) . The mechanism for the blunted rise in 1,25(OH) 2 D production after PTH stimulation is unclear, but FGF23 inhibition of 1,25(OH) 2 D production likely plays a role (73) .
W.M. underwent surgery, and the three parathyroid glands found were described as normal sized, but the excised gland was hyperplastic by microscopy. Hypocalcemia, an increased serum phosphorus level, and tetany followed removal of a single parathyroid gland. These biochemical changes are similar to those in Hyp mice after thyroparathyroidectomy (11). Albright postulated that the rise in serum phosphorus after the partial parathyroidectomy implicated PTH as responsible for the renal phosphate leak in XLH, but additional factors likely contributed to the rise in serum phosphorus because FGF23 is the primary phosphaturic factor in XLH. The persistent hypocalcemia that occurred after parathyroidectomy may provide an explanation. Dietary/serum calcium regulates FGF23 production (Figure 3 ), whereas serum calcium may alter renal phosphate excretion (74) . Although FGF23 levels rise after transient hypoparathyroidism, the level achieved is insufficient to correct the serum phosphorus (75) . This "inadequate" FGF23 response may be protective because a more robust rise in FGF23 could further suppress 1,25(OH)D and PTH production, Figure 4 . A conceptual approach to the PTH resistance in W.M. reported by Albright. The relationship between serum calcium and PTH is bifunctional: PTH is modified by the serum calcium concentration, and, in turn, the serum calcium concentration is modified by PTH. The intersection of these two relationships, PTH ϭ f(Ca) and Ca ϭ f(PTH), can be plotted as shown in Figure 4 , and the intersection of the two function curves is the equilibrium operating point that is the existing value for serum calcium and PTH. Dietary phosphate restriction, besides resulting in a lowering of the serum phosphorus (sP), decreases the amount of PTH needed to maintain a normal serum calcium concentration (open circle inside square) as compared with normals (black circle inside square), or, in other words, shifts the equilibrium operating point to the left; however, in XLH, despite the hypophosphatemia, the equilibrium operating point (gray circle inside square) is shifted to the right of normal, in which more PTH is needed to maintain a normal serum calcium concentration. Similarly, as shown by Albright in W.M., an infusion of PTH resulted in a blunted hypercalcemic response as compared with normals. Also, as shown in comparison with the dietary phosphate-restricted group, the calcemic response to PTH in XLH is much less than that expected for hypophosphatemia. The bifunctional relationship between PTH and calcium shown in this figure was adapted from reference (66). 
Polyostotic Fibrous Dysplasia
In 1937, Albright also reported five cases of an unusual bone disease associated with hyperpigmented skin lesions and endocrinologic abnormalities (3). Albright also reviewed 13 cases from the literature. The patients had bone lesions that were often unilateral and on histologic examination seemed to be osteitis fibrosa. Endocrine dysfunction was frequent and manifested in females by precocious puberty. Metabolic balance data for three of five patients reported by Albright showed normal calcium and phosphate homeostasis, but in one case, serum phosphorus was low, although not commented on by Albright. Since Albright's description, several cases associated with hypophosphatemia, low or inappropriately normal 1,25(OH) 2 D levels, and increased renal phosphate wasting have been reported. FGF23 levels were elevated in these patients, likely from exuberant fibrous dysplasia (79) . Thus, the two syndromes reported in detail by Albright in 1937 may at times share a common pathogenic pathway.
FGF23 as a Phosphaturic Hormone
Genetic disorders are often rare, but Albright understood the broader benefits derived from studying such diseases. This is amply illustrated by the studies of XLH and ADHR, which have markedly expanded our understanding of phosphate homeostasis and its dysregulation in a variety of common and rare disorders (Table 4 ). There is now substantial evidence that FGF23 is involved in normal regulation of phosphate balance (19, 76, 80, 81) . FGF23 expression and serum levels are upregulated by 1,25(OH) 2 D 3 (26,53), and FGF23 levels rise as the phosphate load/serum phosphorus increases (76, 81) (Figure 3 ). Unlike PTH, FGF23 does not seem to function as a rapid re- In this Goldner-stained section from the same patient, the osteoid seam is abnormally wide (center right). There are also several areas of osteoid buried within the mineralized bone (arrows), indicating defective mineralization (arrows). (C) Microradiograph of a bone biopsy from a patient with XLH. There are many enlarged osteocytes, which are seen as opaque areas within the mineralized bone (arrows). In the past, this process was often called osteocytic osteolysis. (D) A normal microradiograph. Newly formed osteons are less dense than older bone, and the opaque areas where osteocytes reside are not prominent. Photographs of the four panels were provided by A.J.F. sponse system but likely plays an important role in long-term regulation of serum phosphorus (81) (82) (83) . These observations are consistent with studies of Hyp mice that demonstrated that FGF23 administration suppressed 1,25(OH) 2 D levels several hours before any changes in serum phosphorus (26). Similarly, FGF23-neutralizing antibodies produced a rise in 1,25(OH) 2 D levels several hours before any changes in serum phosphorus (84) .
FGF23 may play a role in a variety of disorders (Table 4) . FGF23 levels are increased in chronic kidney disease (31, 80, 85, 86) and may be involved in the development of secondary hyperparathyroidism (87) . FGF23 may also be important in the hypophosphatemia observed early after kidney transplantation and in nephrolithiasis associated with a renal leak of phosphate (88, 89) .
Precisely how FGF23 functions is unknown, but it likely exerts its action via FGF receptor 1 (FGFR1; Figure 2) (90) . There are several FGF receptors from separate genes (FGFR1 through 4) (91, 92) . In the parathyroid gland, the FGFR1 is responsible for PTH suppression by FGF23 (65) . Also, an activating mutation in FGFR1 results in the syndrome craniofacial dysplasia with hypophosphatemia (93, 94) . Patients with craniofacial dysplasia with hypophosphatemia have hypophosphatemia and have low levels of 1,25(OH) 2 D 3 , suggesting that FGFR1 is important in the renal action of FGF23. FGFR1 has relatively low affinity for FGF23, but binding of FGF23 to FGFR1 is substantially enhanced by a protein co-factor, klotho (Figure 2 ) (91, 95, 96) . Klotho was first described by Kuro-o et al. (91, 96, 97) as an antisenescence molecule (91, 98, 99) . The N-terminal portion of intact FGF23 is important in binding to FGFR1, whereas the C-terminal portion binds to klotho (84) . Whereas FGFRs are present in many tissues, it seems that klotho confers tissue specificity to the action of FGF23. In the kidney, klotho is expressed primarily in the distal convoluted tubule (DCT) (100) . Analysis of early events after exposure to FGF23 suggests that initial signaling occurs in the DCT, resulting in the postulate that the effects of FGF23 on the phosphate transporter and 1-␣ hydroxylase in the proximal tubule are mediated by a paracrine factor produced by the adjacent DCT (100) (Figure 2) . It is interesting that klotho and FGF23 knockout mice show many of the phenotypic characteristics of aging. Changes in klotho expression may occur with changes in dietary phosphate (101) , but it is unknown whether changes in klotho occur in XLH.
Conclusions
Limited by available technology, Albright did not unravel the pathophysiology of XLH, but his studies provided a strong foundation that enabled subsequent investigators to further our knowledge of XLH. Moreover, new insights into more common disorders with abnormalities in phosphate homeostasis have evolved, as has a greater understanding of the aging process. Although initial studies of PTH levels in XLH failed to corroborate Albright's conclusion that hyperparathyroidism existed in patients with XLH, subsequent studies with newer assays confirmed his hypothesis. After performing detailed studies of W.M., Albright postulated that PTH was the primary phosphaturic factor in VDRR (XLH). This working hypothesis proved incorrect; however, the enduring legacy of Albright in this age of large multicenter trials is that carefully designed, performed, and analyzed studies of only a few patients can provide key insights into the pathophysiologic mechanisms of a disease and generate new hypotheses that can be tested and challenged by future investigators.
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